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ABSTRAK 
 
Arteri dan vena trombosis telah menyumbang kepada peningkatan kadar penyakit dan 
kematian yang ketara. Pencegahan dan rawatan trombosis dapat direalisasikan dengan 
menggunakan ejen antitrombosis. Kurma (Phoenix dactylifera L.) telah dilaporkan 
mempunyai asid salisilik yang tinggi, iaitu sebatian yang bertindak sebagai vitamin K 
antagonis. Oleh itu, kurma berkemungkinan mampu bertindak sebagai antikoagulan. 
Matlamat kajian penyelidikan ini adalah untuk mengetahui pengaruh kurma Ajwa 
(Phoenix dactylifera L.) terhadap penilaian aktiviti pembekuan dalam plasma manusia 
secara in vitro. Plasma dari dua puluh tujuh penderma (n=27) dicampurkan dengan 
ekstrak kurma etanol dan akueus pada kepakatan berbeza iaitu 0.1, 0.5 and 1.0 g/mL. 
Tujuh kumpulan dibentuk bagi setiap plasma penderma: kontrol (saline normal), ET I 
(0.1 g/mL), ET II (0.5 g/mL), ET III (1.0 g/mL), AQ I (0.1 g/mL), AQ II (0.5 g/mL), 
AQ III (1.0 g/mL). Aktiviti pembekuan darah dianalisis melalui prothrombin time (PT), 
activated partial thromboplastin time (APTT) dan thrombin time (TT) bagi kedua-dua 
ekstrak. Tempoh pembekuan PT, APTT dan TT yang panjang dan sangat signifikan  
dilihat pada ET II dan ET III. Tempoh pembekuan PT dan TT yang panjang dan sangat 
signifikan  dilihat pada AQ II dan AQ III. Tempoh pembekuan TT yang panjang dan 
signifikan  dilihat pada AQ I. Pembekuan pada laluan luar dan laluan dalam serta tahap 
pembekuan terakhir dilihat pada kadar kepekatan ekstrak etanol yang sama. Laluan luar 
dan tahap pembekuan terakhir menunjukkan kadar pembekuan yang panjang dan 
signifikan bagi ekstrak akueus. Tahap pembekuan terakhir dilihat lebih terkesan 
berbanding laluan luar kerana pembekuan bermula pada AQ I. Sebagai kesimpulan, 
kurma Ajwa memberi kesan antikoagulan. 
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ABSTRACT 
 
Arterial and venous thromboses contribute to significant morbidity and mortality rate. 
Antithrombotic agent is needed for prevention and treatment of thrombosis. Dates 
(Phoenix dactylifera L.) were reported to have high salicylic acid, a compound 
responsible for anticoagulant by acting as vitamin K antagonist. Thus, dates may have 
anticoagulant effect. The present study was design to assess coagulation activities in 
human plasma treated with Ajwa dates extracts in vitro. Platelet poor plasma (PPP) 
from twenty-seven donors (n=27) were treated with Ajwa dates ethanol and aqueous 
extracts at different concentrations (0.1, 0.5 and 1.0 g/mL). Seven groups were formed 
from each donor: control (normal saline), ET I (0.1 g/mL), ET II (0.5 g/mL), ET III (1.0 
g/mL), AQ I (0.1 g/mL), AQ II (0.5 g/mL), AQ III (1.0 g/mL). In vitro coagulation 
activities of Ajwa dates were assessed by prothrombin time (PT), activated partial 
thromboplastin time (APTT) and thrombin time (TT). Very significant prolongation of 
PT, APTT and TT were observed for concentration ET II and ET III. Very significant 
prolongation of PT and TT were observed for concentration AQ II and AQ III. 
Significant prolongation of TT was observed in AQ I. Coagulation in extrinsic, intrinsic 
and final coagulation systems were prolonged at the same ethanol extract 
concentrations. Extrinsic pathway and final coagulation systems showed prolongation 
by aqueous extract. Final coagulation system was more affected compare to extrinsic 
pathway because prolongation at concentration AQ I was observed. In conclusion, Ajwa 
dates showed anticoagulation effect. 
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CHAPTER I 
 
INTRODUCTION 
 
1.1 Literature Review 
 
1.1.1 Haemostasis  
 
1.1.1.1 Definition 
 
Haemostasis is a dynamic, ordered and well-regulated body process of blood fluids 
maintenance, vascular damage repairing and bleeding arrest (Zehnder 2012, p. 601). 
Haemostasis aims to prevent intravascular blood clot formation and to stop blood loss from 
blood vessel (Estridge & Reynolds 2008). Abnormality in normal haemostasis will disrupt 
the balance maintained in haemostasis mechanism and thus giving rise to two extreme and 
distinct conditions; obstructive intravascular clotting (thrombosis) or excessive bleedings 
(haemorrhage) (Zehnder 2012, p. 601; Sood, 2010). Haemostasis is governed tightly to 
prevent thrombosis and/or haemorrhage by substantial negative feedback mechanism of the 
endothelium and plasma (Shaz et al. 2013) as well as the delicate balance in procoagulant, 
anticoagulant and fibrinolysis process in haemostasis mechanism (Hoffbrand, Moss & 
Pettit 2006). Haemostasis involved five components that define haemostasis in an orderly 
events starting from blood vessels, platelets, coagulation factors, coagulation inhibitors and 
lastly fibrinolysis (Estridge & Reynolds 2008; Hoffbrand, Moss & Pettit 2006). 
Haemostasis is a multistep process that is divided into two; primary and secondary (Fowler 
& Perry 2015; Longo 2013). Primary haemostasis involved the action of the first two 
components of haemostasis, blood vessels and platelets while secondary haemostasis refers 
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to the action of coagulation factors and inhibitors as well as fibrinolysis (Fowler & Perry 
2015). Contrary to Fowler & Perry (2015) statement, Longo (2013) stated that primary 
haemostasis describes the coagulation system while secondary haemostasis describes the 
other factors that contribute to haemostasis for example the blood vessel and platelets. 
 
1.1.1.2 Coagulation in haemostasis 
 
Coagulation is one of the components of haemostasis that follows the establishment of 
blood vessel and platelets action during bleeding (Figure 1.1). When bleeding occurs, 
damaged blood vessel and the regional small arteries and arterioles will constrict to reduce 
blood flow; thereby allowing contact activation of platelets and coagulation factors 
(Hoffbrand, Moss & Pettit 2006). If bleeding is too severe and critical, the cut edges of the 
bleeding site will retract and compressed by contracted skeletal muscles. During this 
retraction and contraction process, small capillary vessels will seal themselves when the 
cut edges touch to one another (Estridge & Reynolds 2008). Then, platelets circulating in 
the blood stream will adhere to the collagen of the exposed connective tissue and caused 
platelets to activate by releasing substances from their granules (Estridge & Reynolds 
2008; Hoffbrand, Moss & Pettit 2006). Adhesion of platelets will be followed by platelet 
aggregation and subsequently blood coagulation in an extremely rapid manner depending 
on von Willebrand factor, fibronectin, divalent cations, calcium, magnesium and 
glycoprotein IIb/ IIIa complex in platelet membrane (Sood 2010). Coagulation of blood is 
determined by coagulation factors and inhibitors (Table 1.1). Coagulation factors include 
plasma proteins factor I till factor XIII (except ionized calcium; previously known as 
Factor IV) (Estridge & Reynolds 2008; Hoffbrand et al. 2006). These proteins are produce 
in the liver and remains in the blood in inactive form. However, when blood vessel is 
damaged, haemostasis signals the activation of coagulation factors, leading to the 
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formation of fibrin clot (Estridge & Reynolds 2008). On the other hand, coagulation 
inhibitors include tissue factor pathway inhibitor (TFPI), heparin cofactor II, α2-
Macroglobulins, α2-antiplasmin, C1 esterase inhibitor and α1-antitrypsin (Hoffbrand, Moss 
& Pettit 2006). When fibrin clot is formed, bleeding will slowly stop as the site of injury is 
healing. At this point, fibrinolysis is needed to dissolve fibrin clot by the action of 
plasminogen and plasmin. Activation of plasminogen to plasmin is stimulated from injured 
vessel wall or from tissues (Hoffbrand, Moss & Pettit 2006). To sum it all, primary 
haemostasis takes place when sub-endothelial of collagen is exposed; signalling the 
initiation of platelet adhesion, granule secretion and initial aggregation. Following primary 
haemostasis, thrombin generation and fibrin clot formation marked the hallmark of 
secondary haemostasis (Fowler & Perry 2015). 
 
1.1.1.3 Coagulation pathway 
 
Coagulation process is best understood through coagulation pathway. Complex interaction 
between coagulation factors and inhibitors is shown through three pathways; intrinsic, 
extrinsic and common (Figure 1.1). Coagulation cascade describe the action of each factors 
in contributing to the final formation of fibrin clot while preventing thrombosis formation 
(Table 1.1 and Figure 1.1). In this cascade, the common pathway is activated by either the 
extrinsic or intrinsic pathway or by interaction between these two pathways (Estridge & 
Reynolds 2008). Tissue factor or alternatively known as FIII or thromboplastin does not 
present in the circulating blood, hence the name extrinsic pathway (Estridge & Reynolds 
2008). Initiation of extrinsic pathway by TPFI occurs during vessel damages (trauma) 
(Estridge & Reynolds 2008). With the presence of calcium, FVII will be activated and 
subsequently activating FX (Estridge & Reynolds 2008). Intrinsic pathway is named 
because the factors involved in this pathway are circulating in the blood (Estridge & 
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Reynolds 2008). Intrinsic pathway is initiated when FXII or alternatively known as contact 
factor is activated by damaged surface (Estridge & Reynolds 2008). Activated FXII will 
then subsequently activate FXI and the subsequent activated FXI will activate FIX 
(Estridge & Reynolds 2008). Activated FIX will participate in the activation of FX that 
will convert prothrombin to thrombin (Estridge & Reynolds 2008). In common pathway, 
fibrinogen will be converted to fibrin by thrombin. With the aid of activated FXIII, fibrin 
clot will form and stabilized when fibrin cross-linked each other (Estridge & Reynolds 
2008; Hoffbrand, Moss & Pettit 2006).  
 
1.1.1.4 Haemostatic screening assay 
 
Defects in haemostasis may arise from vascular disorders, thrombocytopenia or platelet 
function disorder as well as problems in blood coagulation. Due to these reasons, screening 
test for blood coagulation disorders are platelet count, thrombin time (TT), prothrombin 
time (PT), activated partial thromboplastin time (APTT) and fibrinogen quantitation 
(Estridge & Reynolds 2008; Fowler & Perry 2015; Hoffbrand, Moss & Pettit 2006). With 
regard to assessment of coagulation activity; PT, APTT and TT are used to evaluate 
common and extrinsic pathway; common and intrinsic pathway; and final coagulation 
stage respectively (Estridge & Reynolds 2008; Fowler & Perry 2015; Hoffbrand, Moss & 
Pettit 2006; Torres-Urrutia et al. 2013). Battery of test is compulsory when assessing 
coagulation abnormalities because no single test is capable to sufficiently detect such 
abnormalities (Sood 2010).  PT, APTT and TT served as initial screening for clotting 
factor activity (Longo 2013) and also regarded as functional tests because they monitored 
the formation of clot. PT measures fibrinogen (Hoffbrand, Moss & Pettit 2006), FII, FV, 
FVII and FX while APTT measures FX, FV, FII, fibrinogen (Hoffbrand, Moss & Pettit 
2006), FVIII, FIX and FXI (Fowler & Perry 2015; Hoffbrand, Moss & Pettit 2006). 
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Concerning haemostatic studies, samples collected for evaluation is highly sensitive and 
susceptible to even smallest changes in samples integrity (Bennett, Lehman & Rodgers 
2007; Kitchen, Olson & Preston 2009).  Therefore, good performance of haemostatic assay 
will requires consistency, reproducibility and continuous accurate result over time with 
critical attention to the preservation of samples integrity (Kitchen, Olson & Preston 2009). 
Knowledge on pre-analytical variables and the consequences in determining precise result 
is at utmost importance in coagulation laboratory (Kitchen, Olson & Preston 2009). Factors 
that compromised samples integrity include patient’s condition (Kitchen, Olson & Preston 
2009), anticoagulant concentration, container materials, collection technique, 
centrifugation and storage (Bennett, Lehman & Rodgers 2007).  Among all coagulation 
tests available, PT has long been the most frequently used test in evaluating coagulation 
activity since the first establishment of this test on 1983 (Kitchen, Olson & Preston 2009). 
Worldwide, PT is regarded as the sensitive test for most coagulation factors depressed by 
vitamin K antagonist (VKA) (Bennett, Lehman & Rodgers 2007). When coupled with PT 
and APPT assay, differential diagnosis of bleeding disorders is achievable with the 
addition Complete Blood Count (CBC) test that reveals the number of platelet count and 
rather a very useful parameter in diagnosis of haemostasis disorders (Bennett, Lehman & 
Rodgers 2007). However, haemostasis screening test (PT, APTT, fibrinogen level and 
platelet count) has inadequate clinical correlation with actual bleeding risk (Fowler & 
Perry 2015). 
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Table 1.1 Coagulation Factors and Inhibitors (Hoffbrand, Moss & Pettit 2006) 
Coagulation Factors Coagulation Inhibitors 
Factor No. Descriptive name 
I  Fibrinogen TFPI 
Heparin cofactor II 
α2-Macroglobulins 
α2-antiplasmin 
C1 esterase inhibitor 
α1-antitrypsin 
Protein C  
Protein S  
Antithrombin III  
II  Prothrombin 
III  Tissue factor 
V  Labile factor 
VII Proconvertin 
VIII Antihaemophilic factor 
IX Christmas factor 
X Stuart-Prower factor 
XI Plasma thromboplastin antecedent 
XII Hageman (contact) factor 
XIII Firbrin-stabilizing factor 
Prekallikrein (Fletcher factor) 
High Molecular Weight Kininogen 
(HMWK) 
 
 
1.1.1.5 Disorders of defective haemostasis 
 
Defects in any of haemostasis components will eventually caused haemostasis disorders 
(Sood 2010). Haemostasis disorders are grouped based on the aetiology factors. Disorders 
of haemostasis include those of platelets and vessel walls; coagulation; arterial and venous 
thrombosis; and pulmonary thromboembolism (Longo 2013). Coagulation-related 
disorders derived from congenital or acquired abnormalities; with acquired-coagulation 
disorders dominating most of the cases (Longo 2013; Sood 2010). Coagulation disorders 
are tabulated as follows (Table 1.2).  
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Figure 1.1 The more in-depth version of the coagulation cascade (Joe Dunckley 2007). 
TFPI; tissue factor pathway inhibitor, a; activated. Red line represents negative feedback 
and green line represents positive feedback.  
 
Since the heart of coagulation mechanism is regulated by coagulation factors, the 
coagulation-inhibitory and fibrinolytic systems are maintained to obtain delicate balance in 
preventing accidental intravascular clotting while simultaneously sustained the patency of 
vascular lumen post-intravascular clotting (Sood 2010). Table 1.2 shows how one factor 
deficiency or other acquired factors may cause disorder with bleedings as the major 
outcome (Longo, 2013; Sood 2010).  In diagnosing bleeding disorders, comprehensive 
understanding of haemostatic mechanism is a must (Zehnder 2012, p. 601). While 
diagnosis of coagulation disorders depends mostly on the clinical evaluation, laboratory 
results of coagulation test will confirm the diagnosis (Sood 2010). Eventhough each 
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disorder has specific treatment and management; correction of coagulation abnormality by 
drugs tends to be more specific to certain limited disorders while replacement therapy with 
whole blood, fresh frozen plasma or factor concentrates has more wide indications (Sood 
2010).  
 
Table 1.2 Coagulation disorders derived from congenital or acquired abnormalities. 
Aetiology Coagulation disorders Reference 
Congenital Haemophilia A (FVIII) and Haemophilia B(FIX) (most 
common; X-linked recessive)  
Deficiency in FII, FV, FVII, FX, FXI, FXIII and 
fibrinogen (rare; autosomal recessive)  
FXII (Hageman factor deficiency) 
Fletcher factor (pre-kallikrein deficiency) 
Fitzgerald factor (high molecular weight kiningen 
deficiency) 
Longo 2013 
Sood 2010 
 
Von Willebrand’s Disease  Sood 2010 
Acquired Haemorrhagic diathesis of liver disease 
Disseminated Intravascular Coagulation (DIC) 
Vitamin K deficiency 
Longo 2013 
Sood 2010 
 
Anticoagulant drugs 
Acute primary fibrinolysis 
Massive transfusion of stored blood 
Circulating inhibitors of coagulation causing bleeding in 
recognized DIC in wide variety of disorders 
Sood 2010 
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1.1.1.6 Anti-coagulant drugs 
 
Imbalanced haemostatic activity may resulted in thrombosis or bleeding (Sood 2010; 
Zehnder 2012, p. 601). Thrombosis formation in blood vessel is harmful when blood 
coagulation cascade is unchecked by inoperative coagulation inhibitor, blood flow and 
fibrinolysis (Hoffbrand, Moss & Pettit 2006). Significant morbidity and mortality events 
accounted by arterial and venous thromboses (Weitz 2013, p. 277). Arterial thrombosis 
commonly causes acute myocardial infarction (MI), ischemic stroke and limb gangrene, 
which can progress to fatal pulmonary embolism and postphlebitic when deep-vein 
thrombosis occurs (Weitz 2013, p. 277). Venous thrombosis is rare but occurs at vascular 
disruption site, post-surgical trauma and indwelling venous catheters (Weitz 2013, p. 277). 
Prevention and treatment of thrombosis can be realized by the use of antithrombotic agents 
that are grouped into three; antiplatelets, anticoagulants and fibrinolytic drugs (Weitz 2013, 
p. 277).  Antithrombotic agents have been used in clinical settings for more than 50 years 
and becoming one of the most frequently prescribed medications (Patriquin & Crowther 
2013, p.477). Antiplatelet agents include aspirin, thienopyridines, dipyridamole, 
glycoprotein IIB/IIIA receptor antagonist; anticoagulant agents include heparin, low-
molecular-weight heparin, fondaparinux, warfarin, dabigatran, rivaroxaban, apixaban; and 
fabrinolytic agents include streptokinase, anisteplase, urokinase, alteplase, tenecteplase and 
reteplase (Weitz 2013, p. 277). Antithrombotic agents can be taken orally or parenterally 
for various indications (Patriquin & Crowther 2013, p.477). Antiplatelets along with 
anticoagulants and fibrinolytic agents are mostly used to inhibit or treat arterial thrombosis 
since the pathophysiology of arterial thrombosis comprises of high amount of platelets due 
to the fleece-injured arteries. On the other hand, anticoagulants alone are the backbone for 
prevention and treatment of venous thromboembolism (VTE) due to the fact that fibrin 
predominantly contributes to such condition while fibrinolytic drugs served as therapeutic 
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agent for patients with VTE (Weitz 2013, p. 277). The main goal of anticoagulant therapy 
is to prevent unwanted clot formation in patient with artificial heart valve, phlebitasis, 
circulatory problems and joint replacement (Estridge & Reynolds 2008). Heparin and 
warfarin are the infamous antithrombotic agents most frequently used in clinical settings 
(Patriquin & Crowther 2013, p.477). However, current anticoagulant therapy demonstrated 
the use of recently-developed multiple novel agents such as dabigatran, rivaroxaban and 
apixaban that tackles issues associated with traditional agents; for example dosing 
variability, difficult monitoring, drug-drug and drug-environment interactions (Patriquin & 
Crowther 2013, p.477). Data on adverse drugs events showed warfarin and antiplatelets 
agents as one of the main factors contributing to emergency hospitalization in older 
patients (Budnitz et al. 2011). Anticoagulant therapy requires meticulous and details 
monitoring in providing the utmost therapeutic benefits but maintaining safe balance 
between preventing thromboembolic events and side effects (Patriquin & Crowther 2013, 
p.477). Two serious issues associated with antithrombotic therapy that often being brought 
up in medicolegal proceedings are failures to prescribe anticoagulants when clinically 
indicated and insufficient monitoring once therapy started (Patriquin & Crowther 2013, 
p.477).  
 
1.1.2 Dates  
 
1.1.2.1 Overview 
 
Dates (Phoenix dactylifera L.) belongs to the Arecaceae family and has been cultivated for 
over 6000 years ago (Alkaabi et al. 2011) and the most common and vital fruit crop in 
Middle East (Mohamed et al. 2014). Dates are best categorized into the stage of ripening; 
Kamiri (stage 1), Khalal (stage 2), Rutab (stage 3) and Tamar (stage 4) (Alkaabi et al. 
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2011). There are various types of dates; Ajwa, Munifi, Hilali, Ruthana, Khodry, Khalas, 
Sukkary, Sefri and Segae with each of them have roles in diverse disease prevention 
(Rahmani et al 2014). In terms on nutrients, dates have high carbohydrate content (70–
80%), fat (0.20–0.50%), protein (2.30–5.60%), dietary fiber (6.40–11.50%), minerals 
(0.10–916 mg/100 g dry weight), and vitamins (C, B1, B2, B3 and A) with very little or no 
starch (Mohamed et al. 2014). The phytochemical constituents of dates include alkaloids, 
flavonoids, steroids, tannins, estertepens, vitamins and phenolic acids (Onuh et al. 2012). 
The health benefits derived from dates are diverse and expanding including 
antihyperlipidemic, anticancer, gastroprotective, hepatoprotective, nephroprotective 
properties (Mohamed et al. 2014); anti-oxidant, anti-inflammatory, anti-bacterial (Rahmani 
et al 2014); and used for anaemia, stroke and tooth ache treatment, weight-gain and anti-
aging (Onuh et al. 2012). Onto the medicinal value of specific type of dates; Ajwa, the 
Saudi Arabia and/or Madinah Al-Munawara-cultivated dates posed significant value in 
several types of diseases cure as well as protective effect in hepatic toxicity (Rahmani et al 
2014).  
 
1.1.2.2 Dates rich in salicylic acid 
 
Dates have very high concentration of salicylic acid, which is more than 1 mg/100g (What 
is salicylic acid 2014). To our knowledge, there is one available scientific study that 
reported the salicylic acid content in dates (Swain, Dutton & Truswell 1985). Swain & 
Dutton (1985) studied the concentration of salicylic acid using High Performance Liquid 
Chromatography (HLPC) on 333 foods. Swain, Dutton & Truswell (1985) reported that 
fresh dates have 3.75 mg/100g salicylic acid while dried dates have 4.50 mg/100g salicylic 
acid. Salicylic acid is the compound that has the ability to block the action of vitamin K 
during coagulation pathway activation and act as a vitamin K antagonist (Roncaglioni et al. 
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1988). Previously, oral anticoagulant therapy was synonym to oral Vitamin K antagonist 
(VKA) especially in North America where warfarin is referred as VKA (Patriquin & 
Crowther 2013, p.477). This marked the importance of VKA action as an anticoagulant. 
Thus, dates may have anticoagulant effect. In an animal study, salicylates at moderate dose 
may prevent thrombus formation while limiting bleeding complications (Roncaglioni et al. 
1998). Roncaglioni and team demonstrated that salicylates have anticoagulant effect 
comparable to warfarin when the animals administered with 175 mg/kg salicylates were 
compared to animal administered with 0.1-0.2 mg/kg warfarin.  
 
1.1.2.3 Dates and hemostatic activities 
 
To our knowledge, there is no scientific report on the relationship between dates and 
haemostatic activities. On a closely related study, Onuh et al. (2012) had reported a study 
on the effect of dates extracts on peripheral blood parameters using animal model. Their 
study concluded a dosage dependent significant increase in absolute values, red blood cell 
(RBC), Hemoglobin (Hb), Pack Cell Volume (PCV), reticulocytes and platelets. In relation 
to haemostatic activities, platelets count were seen significantly increased in rats treated 
with both ethanolic and aqueous crude dates extracts for a continuous 112 days. Increment 
in platelet counts suggests pro-coagulant effect on haemostatic activity. While there is no 
available scientific data on the correlation between dates and haemostatic activities, many 
scientific data has been published on antithrombotic effects of fruits, vegetables and spices 
as published by Torres-Urrutia et al. (2013).  
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1.1.3 Salicylic acid 
 
1.1.3.1 Salicylic acid in human 
 
Salicylic acid (2-hydroxybenzoic acid) is produced when acetylsalicylic acid (2-
acetoxybenzoic acid) hydrolized (Figure 1.2). In human liver and blood, aspirin 
(acetylsalicylic acid) will be immediately converted to salicylic acid once ingested into the 
body (Duthie et al. 2005). Salicylic acid bound to plasma proteins and circulated in the 
blood and distributed to all tissues in the body (Duthie et al. 2005) especially synovial 
cavity, central nervous system and saliva (Hare, Woodside & Young 2003). Apart from 
serum, salicylic acid may be found in the urine. A study found that diet rich in salicylic 
acid by vegetarians surprisingly showed overlapping serum and urinary salicylates 
concentration in comparison to those taking low-dose aspirin; indicating prominent 
absorption of salicylic acid from ingested fruits and vegetables (Battezzati 2006; Duthie et 
al. 2005). Aspirin (acetylsalicylic acid) is analgesic, anti-thrombotic and anti-inflammatory 
(Scotter et al. 2007). Other than possible antithrombotic effect, acetylsalicylates may 
benefit human health by preventing colon cancer, pregnancy induced pre-eclampsy and 
worked as prophylactic agent against coronary heart disease at concentration as low as 30 
mg/day (Venema et al. 1996).  
 
1.1.3.2 Salicylic acid in foods and dates 
 
Salicylic acid presents in many foods including fruits, vegetables, herbs, spices and vary in 
concentration (Battezzati 2006).  Data on the salicylates content of foods are scarce and 
contradictory (Scotter 2007; Venema et al. 1996). On a study reported by Venema et al. 
(1996), low salicylic acid and no acetylsalicylic acid was detected in foods thought to have 
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high salicylates as published in the literature by fellow researchers. Salicyclic acid in food 
is often associated as natural blood thinner referring to food that has the ability to reduce 
blood. Salicylic acid has been reported to act as vitamin-K antagonist by lowering plasma 
levels of vitamin-K dependent clotting factors as well as inhibiting vitamin-K 
carboxylation in the liver (Roncaglioni et al. 1988). Therefore, a diet rich in acetylsalicylic 
acid should have an antithrombotic effect (Venema et al. 1996). Since dates have been 
claimed to have very high salicylic acid, it may suggest that dates might influenced 
haemostatic activity. However, low level of salicylates in normal diet probably insufficient 
to give physiological effect in vivo (Venema et al. 1996) and subsequently affect disease 
risk (Janssen et al. 1997). Determination of salicylic acid in foods (Swain, Dutton & 
Truswell 1985; Venema et al. 1996) and soups (Baxter et al. 2001) implied the use of 
HPLC in earlier studies. HPLC was also used in the determination of salicylates in 
biological samples such as serum (Blacklock et al. 2001), urinary salicylates (Janssen et al. 
1996) and plasma (Dadgar et al. 1985). Application of gas-chromatography mass 
spectrometry (GCMS) was later applied in the determination of salicylic acids in plants 
(Deng et al. 2003; Engelberth et al. 2003) and human serum (Battezzati 2006). Scotter et 
al. (2007) came with an optimised method of salicylic acid determination in 76 foods using 
GCMS. A highly specific, rapid and cost effective method was developed for 
quantification of salicylic acid and acetylsalicylic acid (Scotter et al. 2007). GCMS is 
preferable because HPLC is lengthy and likely to be affected with interference especially 
when UV detection method is used (Scotter et al. 2007). Eventhough HPLC with 
fluorescence detection method is able to successfully determined salicylic acid in plants; 
samples need to undergo complex purification procedure to isolate salicylic acid from 
other fluorescent compounds of the same plants (Engelberth et al. 2003). Thus, GCMS 
provide a dependable method for separating, identifying and quantifying salicylic acid 
from samples that has undergo carboxylic acids derivatization (Engelberth et al. 2003). 
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Acetylsalicylic Acid (C9H8O4) Salicylic Acid (C7H6O3) 
  
 
Figure 1.2 Skeletal formulas of acetylsalicylic acid and salicylic acid (Fvasconcellos 
2008).  
 
1.1.3.3 Mechanism of action 
 
Understanding of salicylic acid as vitamin K antagonist requires comprehensive knowledge 
on vitamin K mechanism of action. History of vitamin K as antihaemorrhagic dated since 
more than half century ago when vitamin K was discovered to be able to correct dietary-
induced bleeding in chicks (Vermeer & Schurgers 2000). Thereafter, vitamin K showed 
another profound effect as antihaemorrhagic by prolonging clotting times in obstructive 
jaundice patients and correcting bleeding in newborn with hemorrhagic disease (Kitchens, 
Kossler & Konkle 2013). Vitamin K then has established role in managing excessive 
anticoagulation due to the administration of warfarin, warfarin rodenticides and other oral 
anticoagulants (Kitchens, Kossler & Konkle 2013). The active role of vitamin K in 
coagulation cascade is originally to synthesis prothrombin (FII), however the role of 
vitamin K is expanding and discovered to be essential in functioning FII, FVII, FIX, FX as 
well as protein C, protein S (Bolan & Klein 2013, p.496; Longo 2013; Sood 2010; 
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Vermeer & Schurgers 2000), protein Z (Vermeer & Schurgers 2000) and osteocalcin 
(Bolan & Klein 2013, p.496; Vermeer & Schurgers 2000). Two enzymes involved during 
metabolism and regeneration of vitamin K are γ-glutamylcarboxylase and epoxide 
reductase (Bolan & Klein 2013, p.496; Longo 2013).  Vitamin K is needed as cofactor for 
γ-glutamylcarboxylase during formation of γ-carboxyglutamic acid residues on coagulation 
proteins (Bolan & Klein 2013, p.496; Longo 2013). In turn, γ-glutamylcarboxylase will 
catalyze epoxide reductase for regeneration of reduced vitamin K (Longo 2013).  In 
coagulation cascade, vitamin K- dependent coagulation proteins bind to the calcium and 
phospholipids of activated platelets with the help of γ-carboxyglutamate (Gla) residues and 
eventually improve thrombin formation by speeding up the reaction rate at several orders 
of magnitude (Vermeer & Schurgers 2000). Since Gla has stable divalent anionic charges, 
interaction of Gla and calcium ions allow localization of clotting factors to take place as 
well as building up internal calcium channels (Bolan & Klein 2013, p.496). Warfarin act as 
VKA by blocking the action of epoxide reductase and thus inhibit vitamin K effect (Longo 
2013).  Worldwide, VKA is used for the treatment of patient with developing thrombosis 
risk to inhibit blood coagulation (Vermeer & Schurgers 2000). In clinical practice, marked 
correction of PT test within 6-24 hours post-parenteral vitamin K administration confirmed 
the deficiency of vitamin K (Sood 2010).  
 
1.2 Problem Statement / Research Question        
 
Dates were reported to have high concentration of salicylic acid. Salicylic acid is the 
compound that has the ability to block the action of vitamin K during coagulation pathway 
activation and act as a vitamin K antagonist (Roncaglioni et al. 1988). Thus, dates may 
have anti-coagulation effect. However, an in vivo study by Onuh et al. (2012) on the effects 
of dates extract on blood parameters showed significant increment of platelets count; 
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which may suggest pro-coagulant activity of dates. In addition, literatures have reported 
that dates reduce postpartum haemorrhage (Khadeem et al. 2007); suggesting dates having 
antihaemorrhagic activity. In view of antiplatelet and anticoagulant drugs; aspirin is the 
infamous and mostly used antiplatelet drug (Weitz 2013, p. 277) while warfarin is the most 
widely used oral anticoagulant in the world (Krynetskiy & McDonnel 2007; Patriquin & 
Crowther 2013, p. 477). However, some conventional antiplatelet and anticoagulant drugs 
are associated with adverse events and therapeutic failure. Side-effects of anticoagulant 
drugs include internal bleeding, prolonged bleeding time, palpitation, gastrointestinal 
symptoms and haemorrhage. Aspirin along with other oral anti-platelet drugs account for 
13.3% while warfarin accounts for 33.3% emergency hospitalization for adverse drug 
events in older American (Budnitz et al. 2011). At present time, no ideal anticoagulant 
drugs have ever existed since all anticoagulants and fibrinolytic will increase bleeding risk 
(Zehnder 2012, p. 601). These two claims of dates having high salicylic acid and the 
medicinal value to reduce postpartum haemorrhage as well as significant platelet count 
increment seem to contradict to each other. Therefore, the studies of coagulation activities 
of dates as well as analysis of chemical composition of dates are of great interest. Natural 
products are beneficial remedy because they are cheap and readily available without 
complication and side effects (Rahmani et al. 2014). General supportive measure is needed 
in coagulation disorders (Shaz et al. 2013). Since salicylates enhanced oral anticoagulant 
therapy (Sood 2010), the study of dates as a dietary supplement for patient with 
coagulation problem is highly attentive. On another side, supplements have potential of 
altering haemostatis (Markham & Dog 2013, p. 595); therefore, knowledge on dates as 
pro-coagulant or anti-coagulant food is beneficial in improving human health with 
coagulation-related problem.  
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1.3 Research Objectives 
 
1.3.1 General  
 
To assess coagulation activities in human plasma treated with Ajwa dates (Phoenix 
dactylifera L.) extracts in vitro. 
 
1.3.2 Specific 
 
 1. To determine coagulation activities in human plasma treated with Ajwa dates (Phoenix 
dactylifera L.) extracts at different concentration (0.1, 0.5 and 1.0 g/mL). 
2. To screen chemical compounds of Ajwa dates (Phoenix dactylifera L.) qualitatively 
using gas chromatography-mass spectrometry (GCMS) from ethanol and aqueous 
extracts. 
 
1.4 Research Hypothesis 
 
H0: Ajwa dates (Phoenix dactylifera L.) do not have coagulation effect 
HA: Ajwa dates (Phoenix dactylifera L.) have coagulation effect 
 
1.5 Rationale of Study / Expected Outcome 
 
1. This research concerned about the potential role of dates as anti-coagulant. 
2. This research focused on the improvement of human health by introducing dates as pro- 
or anti-coagulant food. 
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Chapter II 
 
METHODOLOGY 
 
2.1 Study design 
 
This research employed experimental study design with control and treatment groups. 
Dates were extracted with single extraction method using ethanol and aqueous. Venous 
blood was withdrawn from twenty-seven donors (n=27) to be collected into K2-EDTA 
and trisodium-citrate tubes for platelet and coagulation studies respectively. Platelet 
poor plasma (PPP) were treated with Ajwa dates ethanol and aqueous extracts at 
different concentrations (0.1, 0.5 and 1.0 g/mL). Seven groups were formed from each 
donor: control (normal saline), ET I (0.1 g/mL), ET II (0.5 g/mL), ET III (1.0 g/mL), 
AQ I (0.1 g/mL), AQ II (0.5 g/mL), AQ III (1.0 g/mL). In vitro coagulation activities of 
Ajwa dates were assessed by prothrombin time (PT), activated partial thromboplastin 
time (APTT) and thrombin time (TT). Data was analyzed statistically using SPSS 
Version 22.0 (Figure 2.1). Following extraction, both ethanol and aqueous extracts were 
analyzed qualitatively using Gas Chromatography – Mass Spectrometry (GCMS).  
 
2.2 Extraction 
 
2.2.1 Ajwa Dates Collection 
 
This method of dates collection was adapted from Biglari et al. (2007) with few 
modifications. Ajwa dates were purchased from local distribution centre (Yusuf 
Taiyoob Sdn. Bhd., Pulau Pinang, Malaysia). Dates weighed about 4–8g per fruit and 
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for each extraction, approximately 100 g (~16 dates) of dates were used. Dates were 
properly selected in terms of size, colour, ripening stage and quality. The edible part of 
dates (100 g) were pitted and oven-dried for 7 days. 
 
2.2.2 Ethanol Extraction 
 
Pitted dates (100 g) were dry-blended with an analytical mill (IKA, A11 Basic). 
Grounded dates were extracted two times with 200 ml 99.7%, ethanol (QreC) at room 
temperature (20°C, 1H) using ultrasonic cleaner (WiseClean, WUC-A10H). The 
extracts were centrifuged (6000rpm, 10min) and filtered. The supernatant was 
concentrated under reduced pressure (40°C, 3H) using a rotary evaporator (EYELA, 
N1100) to obtain dates ethanolic crude extracts. The crude extracts were kept at 4°C 
until used for analysis.  
 
2.2.3 Aqueous Extraction 
 
This method of aqueous extraction was adapted from Vayalil (2002) with few 
modifications. Grounded dates were extracted two times with 200ml distilled water at 
room temperature (20°C, 1H) using ultrasonication (WiseClean, WUC-A10H). The 
extracts were centrifuged (6000rpm, 10min) and filtered. The supernatant was collected 
and lyophilized using freeze dryer (Christ, Alpha 1-4 LSC) to obtain aqueous crude 
extracts. The crude extracts were kept at 4°C until used for analysis. 
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2.2.4 Yield Percentage (%) Calculation 
 
The percentage of extraction yield was calculated using the following formula (Zhang, 
Bi & Liu 2007).  
Extraction yield (%) = Weight of dried extract × 100 
                                         Weight of original sample 
 
2.3 GC-MS analysis 
 
2.3.1 Crude Extracts Derivatization 
 
This method of chemical derivatization was adapted from Scotter et al. (2007) with few 
modifications. A 1 mL aliquot of crude extract solution (1 mg/mL) was transferred to a 
2 ml glass vial and solvent was removed under a stream of N2 on an evaporator system 
(Glas-Col) at 35°C. The vial was removed as soon as the residue solvent dried.  A 200 
µl of BSTFA/TMCS derivatising agent (Supelco) was added to the vial. The vial was 
capped immediately and heated at 60°C for 1 H with occasional swirling.  The solution 
was cooled to room temperature prior to analysis by GC–MS (Agilent, 7890A). 
 
2.3.2 Analysis of Compounds 
 
This method of GC-MS analysis was adapted from Deng et al. (2003). Analysis was 
done using HP-5ms capillary column (30m, 0.25mm, 0.25µm) equipped with MSD 
5975C detector and spitless injection system. Helium gas (99.999%) was used as a 
carrier gas at a flow rate of 1 mL/min. The oven temperature was set at 100°C for 2 min 
then programmed at 15° C/min to 300°C which was maintained for 10 min. The results 
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were analyzed qualitatively in full-scan acquisition mode with a mass range of 45–500 
a.m.u. The compounds were identified using NIST database. Identification was made by 
comparing mass spectra of each compound with the compound in NIST database for 
matching quality. 
 
2.4 Assessment of Coagulation Activities 
 
2.4.1 Sample Size Calculation 
 
By using Power and Sample software (Dupont & Plummer 1997) which based on paired 
t-test formula; result showed as follows: α = 0.05, δ= 0.345 (detectable difference at 
60%), σ= 0.575 (based on coagulation activity result (Torres-Urrutia et al. 2011), power 
= 0.8 (80%), n = 27 (plus 10% drop out rate) for subject group. 
 
2.4.2 Donor Recruitments 
 
Twenty-seven donors (n=27) were recruited at Clinical Trial Complex, Advanced 
Medical and Dental Institute (AMDI), USM. All donors were informed about the 
objective of this study and had signed informed consent form prior to blood collection. 
The protocol was authorized by Human Research Ethics Committee (HREC), USM. 
Inclusion criteria include all the criteria for blood donation as stated by National Blood 
Centre (PDN). Inclusion criteria includes male or female; age range between 18-60 
years old; healthy and free from clinical disorders; body weight of more than 45 kg; had 
taken food before donating blood; not pregnant, not breast-feeding, menstrual period on 
day-5 onwards and do not involved in any risk activities. Exclusion criteria include had 
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taken antiplatelets/anticoagulant/fibrinolytic drugs, vitamin/mineral supplements or 
medication for at least 7 days before recruitment.  
 
2.4.3 Blood Collection  
 
For platelet count, 3 mL blood was collected in K2-ethylene-diamine tetraacetic acid 
(EDTA). For coagulation studies, 6 mL blood was collected in trisodium citrate tube 
(3.2%) in a 9:1 ratio. Blood was centrifuged (6000rpm, 10min)   to obtain PPP (platelet-
poor plasma) and analyzed immediately.  
 
2.4.4 Platelet Count 
 
Platelet count was determined using automated hematology analyzer (Sysmex, KX-21). 
The result of platelet count was expressed in number of platelets per microlitre of blood. 
 
2.4.5 Measurement of coagulation factors 
 
This method of anticoagulant activity study was adapted from Karim, Noor & Seman 
(2013). PT, APTT and TT tests were conducted using an automated coagulation 
analyzer (Diagnostica Stago, STA Compact). The PPP was pre-incubated (37°C, 7min) 
with crude extract solutions at 1:1 (v/v) with concentration 0.1 g/mL, 0.5 g/mL and 1 
g/mL. The results of coagulation tests were expressed in seconds (s).  
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2.4.6 Sample Disposal 
 
Excess samples from this research were not used for other reasons and were destroyed 
with the consent from Human Research Ethics Committee USM (HREC). 
 
2.5 Statistical Analysis 
 
Statistical analysis was performed using SPSS Version 22.0 (IBM Corp.). The data was 
expressed as median with minimum and maximum range of duplicate determination. 
Kruskal-Wallis with Bonferroni correction was used to compare significance difference 
between control and each treatment group. Values were considered significantly 
different when p<0.05 and very significantly different when p<0.001. 
 
 
 
